Alantolactone triggers oxeiptosis in human ovarian cancer cells via Nrf2 signaling pathway.
Alantolactone
Nrf2 signaling pathway
Ovarian cancer
Oxeiptosis
Journal
Biochemistry and biophysics reports
ISSN: 2405-5808
Titre abrégé: Biochem Biophys Rep
Pays: Netherlands
ID NLM: 101660999
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
05
06
2023
revised:
25
08
2023
accepted:
25
08
2023
medline:
15
9
2023
pubmed:
15
9
2023
entrez:
15
9
2023
Statut:
epublish
Résumé
A growing body of evidence indicated that Alantolactone (ALT) promotes Reactive Oxygen Species (ROS) generation exclusively in cancer cells. Therefore, the aim of this study was to investigate the effect of ALT on the molecular mechanism of oxeiptosis, as a novel cell death pathway due to the high levels of intracellular ROS in ovarian cancer. MTT assay was used to evaluate the effect of ALT on SKOV3 cell viability. mRNA and protein expression levels of Nrf2 (nuclear factor erythroid 2-related factor 2), KEAP1 (Kelch-like ECH-associated protein 1), PGAM5 (phosphoglycerate mutase family member 5), AIFM1 (Mitochondrial Apoptosis-Inducing Factor), Glutathione synthetase (GSS) and glutathione peroxidase (GPX) were analyzed by real time PCR and western blotting methods respectively. Our findings showed that ALT inhibits the proliferation of skov3 cells in a time and dose dependent manner and IC50 was 32 μM at 24h.A significant down-regulation of Nrf2, GSH and GPX mRNA levels was seen in skov3 cells incubated with 32 and 64 μM of ALT in comparison with control group, while, mRNA expression levels of PGAM5 and KEAP1 were increased.Western blot analysis showed that ALT significantly decreases protein levels of Nrf2 and increases PGAM5 and KEAP1.ALT dephosphorylated PS116-AIFM1 and total AIFM1 protein level was elevated. Our results provided evidence that ALT could be a potential option for ovarian cancer treatment by ROS-mediated oxeiptosis.
Identifiants
pubmed: 37712005
doi: 10.1016/j.bbrep.2023.101537
pii: S2405-5808(23)00118-8
pmc: PMC10497985
doi:
Types de publication
Journal Article
Langues
eng
Pagination
101537Informations de copyright
© 2023 The Authors.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.
Références
Biochem Biophys Res Commun. 2008 Aug 15;373(1):151-4
pubmed: 18555005
Histopathology. 2012 May;60(6):943-52
pubmed: 22348534
PLoS Med. 2006 Oct;3(10):e420
pubmed: 17020408
Nature. 2011 Jul 06;475(7354):106-9
pubmed: 21734707
Nature. 2011 Jul 13;475(7355):231-4
pubmed: 21753854
Int J Mol Med. 2019 Sep;44(3):1026-1038
pubmed: 31524219
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
pubmed: 26742998
Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13568-73
pubmed: 18757741
Cancer Chemother Pharmacol. 2018 Apr;81(4):647-658
pubmed: 29464354
Am Soc Clin Oncol Educ Book. 2014;:13-5
pubmed: 24857054
Mol Cell Biol. 2014 Jul;34(13):2382-95
pubmed: 24732804
IUBMB Life. 2012 Sep;64(9):783-94
pubmed: 22837216
Biochem Pharmacol. 2016 Feb 15;102:34-44
pubmed: 26686580
J Pathol. 2010 Mar;220(4):446-51
pubmed: 19967722
Carcinogenesis. 2013 Aug;34(8):1806-14
pubmed: 23563091
J Nat Prod. 2016 Mar 25;79(3):629-61
pubmed: 26852623
Carcinogenesis. 2008 Jun;29(6):1235-43
pubmed: 18413364
Oncol Lett. 2016 Jun;11(6):4203-4207
pubmed: 27313767
Gynecol Oncol. 2015 Nov;139(2):228-35
pubmed: 26383827
Cell Death Differ. 2018 Jul;25(7):1191-1193
pubmed: 29844568
Clin Cancer Res. 2018 Jul 1;24(13):3087-3096
pubmed: 29615460
Food Chem Toxicol. 2012 Sep;50(9):3313-9
pubmed: 22721982
Res Pharm Sci. 2022 Apr 18;17(3):294-304
pubmed: 35531132
J Surg Oncol. 2010 May 1;101(6):500-6
pubmed: 20213688
Gastroenterology. 2008 Oct;135(4):1358-1368, 1368.e1-4
pubmed: 18692501
Cancer Res. 2008 Mar 1;68(5):1303-9
pubmed: 18316592
Diabetes. 2010 Apr;59(4):850-60
pubmed: 20103708
Nat Rev Cancer. 2015 Nov;15(11):668-79
pubmed: 26493647
Int J Mol Sci. 2016 Apr 14;17(4):558
pubmed: 27089328
Biomed Res Int. 2013;2013:719858
pubmed: 23533997
Oncotarget. 2018 Apr 6;9(26):18099-18114
pubmed: 29719593
Mol Med Rep. 2013 Oct;8(4):967-72
pubmed: 23970102
Genes Cells. 2011 Feb;16(2):123-40
pubmed: 21251164
Free Radic Biol Med. 2011 Aug 1;51(3):744-54
pubmed: 21641991
Mol Cancer Ther. 2010 Feb;9(2):336-46
pubmed: 20124447
IUBMB Life. 2013 May;65(5):435-44
pubmed: 23441067
Curr Opin Immunol. 2019 Feb;56:37-43
pubmed: 30342374
Chem Biol Interact. 2013 Oct 25;206(1):100-8
pubmed: 23994249
Mol Cell. 2006 Mar 3;21(5):689-700
pubmed: 16507366
Antioxid Redox Signal. 2017 Jul 10;27(2):106-114
pubmed: 27733046
ScientificWorldJournal. 2013 Oct 27;2013:248532
pubmed: 24288468
Arch Pharm Res. 2018 Mar;41(3):299-313
pubmed: 29214600
Cancer Cell. 2006 Sep;10(3):241-52
pubmed: 16959615
Sci Rep. 2017 Jul 24;7(1):6242
pubmed: 28740138
Nat Immunol. 2018 Feb;19(2):130-140
pubmed: 29255269
Oxid Med Cell Longev. 2016;2016:6475624
pubmed: 26649142
Free Radic Biol Med. 2011 Jun 1;50(11):1599-609
pubmed: 21402146
Clin Cancer Res. 2010 Jul 15;16(14):3743-53
pubmed: 20534738
Int J Cancer. 2020 Feb 1;146(3):749-758
pubmed: 30968402